Skip to Main Content

Author Details

Malcolm C Pike
Memorial Sloan-Kettering Cancer Center
1963
611
114
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
37750771Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.Radiology2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
37436712A framework for assessing interactions for risk stratification models: the example of ovarian cancer.J Natl Cancer Inst2023
36688720Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.J Natl Cancer Inst2023
37750771Association of Breast Cancer Odds with Background Parenchymal Enhancement Quantified Using a Fully Automated Method at MRI: The IMAGINE Study.Radiology2023
37339172The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas.Clin Cancer Res2023
37436712A framework for assessing interactions for risk stratification models: the example of ovarian cancer.J Natl Cancer Inst2023
36401943Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery.Gynecol Oncol2023
36688720Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis.J Natl Cancer Inst2023
36572991CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.Cancer2023
34776242Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.Gynecol Oncol2022
36182623Effects of risk factors for ovarian cancer in women with and without endometriosis.Fertil Steril2022
35700017Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.Cancer Epidemiol Biomarkers Prev2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
36008488MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women.NPJ Breast Cancer2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
35064059Reproductive Factors Do Not Influence Survival with Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2022
35063793Outdoor ambient air pollution and breast cancer survival among California participants of the Multiethnic Cohort Study.Environ Int2022
35315524Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.Int J Cancer2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
34776242Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association.Gynecol Oncol2022
35015210The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.Breast Cancer Res Treat2022
35700017Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System.Cancer Epidemiol Biomarkers Prev2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36182623Effects of risk factors for ovarian cancer in women with and without endometriosis.Fertil Steril2022
36222710Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes.Clin Cancer Res2022
36008488MRI background parenchymal enhancement, breast density and breast cancer risk factors: A cross-sectional study in pre- and post-menopausal women.NPJ Breast Cancer2022
35015210The progesterone-receptor modulator, ulipristal acetate, drastically lowers breast cell proliferation.Breast Cancer Res Treat2022
35315524Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.Int J Cancer2022
35064059Reproductive Factors Do Not Influence Survival with Ovarian Cancer.Cancer Epidemiol Biomarkers Prev2022
35063793Outdoor ambient air pollution and breast cancer survival among California participants of the Multiethnic Cohort Study.Environ Int2022
34789471High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival.Cancer Epidemiol Biomarkers Prev2022
34782936MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma.Virchows Arch2022
32766851Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.J Natl Cancer Inst2021
34013527Risk of breast cancer and prediagnostic urinary excretion of bisphenol A, triclosan and parabens: The Multiethnic Cohort Study.Int J Cancer2021
34048292Development and Validation of a Breast Cancer Risk Prediction Model for Childhood Cancer Survivors Treated With Chest Radiation: A Report From the Childhood Cancer Survivor Study and the Dutch Hodgkin Late Effects and LATER Cohorts.J Clin Oncol2021
33619020Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.Cancer Epidemiol Biomarkers Prev2021
34090707Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.Gynecol Oncol2021
33823904Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.Breast Cancer Res2021
32766851Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies.J Natl Cancer Inst2021
32801014Associations Between Reproductive and Hormone-Related Factors and Risk of Nonalcoholic Fatty Liver Disease in a Multiethnic Population.Clin Gastroenterol Hepatol2021
33105052Pregnancy outcomes and risk of endometrial cancer: A pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium.Int J Cancer2021
34845211Mammographic texture features associated with contralateral breast cancer in the WECARE Study.NPJ Breast Cancer2021
33823904Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study.Breast Cancer Res2021
33619020Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.Cancer Epidemiol Biomarkers Prev2021
  • 1 - 50 of 1,222

Recommended Authors

Jeanine M Genkinger
Mailman School of Public Health, Columbia University
Career Start Year 2001
Number of shared co-authors 25
Dina N Paltoo
National Institutes of Health
Career Start Year 1998
Number of shared co-authors 10
Wanqing Wen
Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center
Career Start Year 1998
Number of shared co-authors 66
Vera J Suman
Mayo Clinic
Career Start Year 1992
Number of shared co-authors 16
Peggy L Porter
Fred Hutchinson Cancer Research Center
Career Start Year 1991
Number of shared co-authors 11
Ruth M Pfeiffer
National Cancer Institute.
Career Start Year 1990
Number of shared co-authors 69
Isabelle Bairati
Laval University Cancer Research Center
Career Start Year 1989
Number of shared co-authors 4
Motomi Mori
St Jude Children's Research Hospital.
Career Start Year 1988
Number of shared co-authors 3
Jeffery P Struewing
National Human Genome Research Institute, National Institutes of Health
Career Start Year 1988
Number of shared co-authors 48
Brent W Zanke
University of Toronto
Career Start Year 1987
Number of shared co-authors 47
Fred C G J Sweep
Radboud University Medical Centre
Career Start Year 1987
Number of shared co-authors 7
Christos Markopoulos
National and Kapodistrian University of Athens
Career Start Year 1987
Number of shared co-authors 1
Fran??ois Meyer
Laval University
Career Start Year 1986
Number of shared co-authors 3
Stefan Aebi
University of Bern
Career Start Year 1985
Number of shared co-authors 5
Dianne M Finkelstein
Harvard Medical School
Career Start Year 1985
Number of shared co-authors 14
Craig D Shriver
Walter Reed National Military Medical Center
Career Start Year 1985
Number of shared co-authors 10
David Tritchler
University at Buffalo
Career Start Year 1984
Number of shared co-authors 7
Marco Mesiti
Universita degli Studi di Milano
Career Start Year 1984
Number of shared co-authors 1
Robin J Bell
School of Public Health and Preventive Medicine, Monash University
Career Start Year 1981
Number of shared co-authors 0
John W Waterbor
University of Alabama at Birmingham
Career Start Year 1979
Number of shared co-authors 3
Scott M Lippman
Moores Cancer Center, university of california san diego
Career Start Year 1977
Number of shared co-authors 20
Kathleen I Pritchard
UCL Great Ormond Street Institute of Child Health, University College London
Career Start Year 1976
Number of shared co-authors 18
Alexander M Walker
Harvard T.H. Chan School of Public Health
Career Start Year 1975
Number of shared co-authors 7
Kenneth C Chu
Ontario Institute for Cancer Research
Career Start Year 1974
Number of shared co-authors 6
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 4
Judith D Goldberg
NYU Grossman School of Medicine
Career Start Year 1974
Number of shared co-authors 1
Veronica Clavijo Jordan
Harvard Medical School
Career Start Year 1971
Number of shared co-authors 4
John J Mulvihill
University of Oklahoma
Career Start Year 1968
Number of shared co-authors 15
Gilbert S Omenn
and School of Public Health, University of Michigan ann arbor
Career Start Year 1965
Number of shared co-authors 1
James N Ingle
Mayo Clinic
Career Start Year 1952
Number of shared co-authors 31

Collaborators

Brian E Henderson
University of Southern California
Co-authored papers 138
Anna H Wu
University of Southern California
Co-authored papers 137
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 114
Marc T Goodman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 83
Andrew Berchuck
Duke School of Medicine
Co-authored papers 83
Jennifer A Doherty
Huntsman Cancer Institute, University of Utah
Co-authored papers 81
Joellen M Schildkraut
Rollins School of Public Health, Emory University
Co-authored papers 80
Mary Anne Rossing
Fred Hutchinson Cancer Research Center
Co-authored papers 71
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 71
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 69
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 67
Jenny Chang-Claude
German Cancer Research Center (DKFZ)
Co-authored papers 66
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 65
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 64
Laurence N Kolonel
Co-authored papers 64
Aleksandra Gentry-Maharaj
UCL EGA Institute for Women's Health, University College London
Co-authored papers 62
Alice S Whittemore
Co-authored papers 58
Hoda Anton-Culver
University of California irvine
Co-authored papers 58
Lynne R Wilkens
University of Hawaii Cancer Center
Co-authored papers 57
Nicolas Wentzensen
National Cancer Institute, National Institutes of Health
Co-authored papers 56
Daniel O Stram
Co-authored papers 54
Elisa V Bandera
Co-authored papers 54
Honglin Song
University of Cambridge
Co-authored papers 51
Weiva Sieh
Co-authored papers 49
Georgia Chenevix-Trench
QIMR Berghofer Medical Research Institute
Co-authored papers 48
Leslie Bernstein
Co-authored papers 47
Louise A Brinton
National Cancer Institute
Co-authored papers 46
Brooke L Fridley
H. Lee Moffitt Cancer Center and Research Institute
Co-authored papers 46
Pamela J Thompson
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 46
Jolanta Lissowska
The M. Sklodowska-Curie Cancer Center and Institute of Oncology
Co-authored papers 43
Release 1.2